Skip to main content
. 2019 Feb 13;33(8):2006–2021. doi: 10.1038/s41375-019-0403-2

Fig. 6.

Fig. 6

Chemical inhibition of RUNXs potentiates lenalidomide toxicity in primary multiple myeloma cells. a Primary MM cells were treated with DMSO, 0.1 μM lenalidomide, 1 μM AI-10-104, and combination. Every 2 days, viable cells were counted using Trypan blue exclusion assay. b The historical treatments of five MM patients are shown